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Abstract
PMEL is a pigment cell-specific protein that forms physiological amyloid fibrils upon which melanins ultimately deposit in
the lumen of the pigment organelle, the melanosome. Whereas hypomorphic PMEL mutations in several species result in a
mild pigment dilution that is inherited in a recessive manner, PMEL alleles found in the Dominant white (DW) chicken and
Silver horse (HoSi)—which bear mutations that alter the PMEL transmembrane domain (TMD) and that are thus outside the
amyloid core—are associated with a striking loss of pigmentation that is inherited in a dominant fashion. Here we show that
the DW and HoSi mutations alter PMEL TMD oligomerization and/or association with membranes, with consequent
formation of aberrantly packed fibrils. The aberrant fibrils are associated with a loss of pigmentation in cultured
melanocytes, suggesting that they inhibit melanin production and/or melanosome integrity. A secondary mutation in the
Smoky chicken, which reverts the dominant DW phenotype, prevents the accumulation of PMEL in fibrillogenic
compartments and thus averts DW–associated pigment loss; a secondary mutation found in the Dun chicken likely dampens
a HoSi–like dominant mutation in a similar manner. We propose that the DW and HoSi mutations alter the normally benign
amyloid to a pathogenic form that antagonizes melanosome function, and that the secondary mutations found in the
Smoky and Dun chickens revert or dampen pathogenicity by functioning as null alleles, thus preventing the formation of
aberrant fibrils. We speculate that PMEL mutations can model the conversion between physiological and pathological
amyloid.
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Introduction
Amyloid fibrils are polymers of single proteins that oligomerize
and assemble into a characteristic fibrillar structure with a cross-
beta sheet backbone [1,2]. Amyloid formation is typically
associated with pathologies, such as the Ab aggregates in
Alzheimer Disease or prion aggregates in inherited or acquired
spongiform encephalopathies. However, the amyloid fold has also
been exploited for functional means in prokaryotes, lower
eukaryotes and even in mammals [2–6]. The structural and
biogenetic features that distinguish functional from pathological
amyloid are not well understood. Discerning these features might
lead to novel therapies for amyloid diseases.
A potential model for distinguishing functional from patholog-
ical amyloids is the pigment cell-specific integral membrane
glycoprotein, PMEL (also called gp100, Pmel17, or Silver) [7,8].
Functional amyloid fibrillar sheets, composed largely of lumenal
proteolytic fragments of PMEL, form the structural foundation of
eumelanosomes, which are membrane-bound, pigment cell-specific
lysosome-related organelles within which black and brown melanin
pigmentsaresynthesizedand stored[9,10].Thefibrilsbegintoform
in association with intralumenal membrane vesicles (ILVs) within
multivesicular melanosome precursors [11,12], to which PMEL is
selectively delivered during biosynthetic transport [13,14]. Either in
the trans Golgi network [15] or in association with the ILVs or with
membrane domains destined for the ILVs [16], PMEL is cleaved by
two site-specific proteases to liberate a lumenal fragment called Ma
[13,14,16–18] (see Figure 1). Ma then undergoes ordered oligo-
merization into protofibrils that are detergent insoluble [17],
detectable by electron microscopy (EM) [11,13,14,17], and reactive
with amyloidogenic dyes [19]. The Ma fibrils are further matured
by proteolytic processing [20–23] and assemble into sheets [11,24],
upon which melanins deposit as they are synthesized during
melanosome maturation [10,24]. In vitro, denatured recombinant
Ma fragments that are diluted into non-denaturing buffers rapidly
assemble into fibrils that are classified as amyloid by a number of
biophysical measures [19,23,25]. The physiological function of the
fibrils is not entirely clear, but they likely serve to condense melanin
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or intercellular or intracellular transfer [8]. This function seems to
be important for optimal pigmentation, as animal models with
apparently hypomorphic mutations in PMEL show varying levels of
hypopigmentation, ranging from modest in the silver mouse [26] to
more pronounced in Merle dogs [27] and fading vision zebrafish [28].
In the accompanying paper by Hellstro ¨met al. [29], we show that a
complete loss of PMEL expression in the Pmel
-/- mouse also
presents with a modest pigment dilution.
Compared to the more modest effects of the PMEL mutations
described above, genetic models in the chicken and horse show
that in some cases, PMEL mutations can result in severe
hypopigmentation. In the chicken, a nine bp in-frame insertion
within the coding region for the PMEL transmembrane domain
(TMD; TM
insWAP) is associated with the nearly complete loss of
feather eumelanin in Dominant White (DW) chickens [30]. The
pigment loss in DW chickens is associated with poor melanocyte
survival in culture and with melanocyte depletion along the feather
shaft in vivo [31], both exaggerations of the increased cell cycle
length [32] and slow, progressive melanocyte loss [33] observed in
homozygous mice bearing the recessive, hypomorphic PMEL silver
mutation. However, unlike mouse silver, the DW allele is associated
with impaired melanosome maturation and with melanosome loss
within epidermal melanocytes [34,35]. Moreover, the DW allele
differs from mouse silver and other PMEL hypomorphs in that it
confers hypopigmentation in a dominant fashion, suggesting that
the DW PMEL product must either inhibit endogenous PMEL
function in a dominant-negative manner or confer some gain-of-
function that is detrimental to melanocyte function and/or health.
Interestingly, a concomitant deletion within the conserved lumenal
Polycystic Kidney Disease-1 homology (PKD) domain in the Smoky
chicken (PKD
DLVVT) reverts the dominant phenotype of the
TM
insWAP DW mutation, resulting in a much more modest
hypopigmentation that is inherited in a recessive manner [30]. In
Silver horses (HoSi), a dominant missense mutation in PMEL results
in a transversion that substitutes a cysteine for the second of three
consecutive arginine residues immediately following the PMEL
TMD (TM
R625C), causing a dilution of black pigment that is most
noticeable in the mane and tail of the animal [36,37]. An
orthologously identical TM
R625C mutation in the Dun chicken
PMEL allele is accompanied by an additional gene deletion
(TM
D5) that eliminates five residues from the PMEL TMD [30].
However, while Dun is likewise dominant, it confers a more modest
hypopigmentation, suggesting either species-specific variation in
the TM
R625C PMEL phenotype or that the TM
D5 secondary
mutation might partially dampen the pigmentation defect that the
TM
R625C mutation confers individually. Why the mutations in the
DW chicken and Silver horse present a dominant phenotype and
how they might be reverted by the additional deletions in the
Smoky and (perhaps) Dun chickens is not understood.
Given the severity of their pigmentation phenotype, the
association with loss of melanosome integrity and melanocyte
Figure 1. Schematic diagram of PMEL proteolytic processing. Diagram of PMEL domain structure, relevant proteolytic fragments and
proteolytic cleavage sites (dashed lines and scissors). Within the primary sequence are indicated the signal peptide (S), N-terminal region (NTR),
polycystic kidney disease repeat domain (PKD), repeat domain (RPT), transmembrane domain (TM) and cytoplasmic domain (Cyto). The signal peptide
is removed from the N-terminus of PMEL in the ER by signal peptidase (SP). PMEL is cleaved by a proprotein convertase (PC) to produce Ma and Mb
fragments, which are linked by disulfide bonds (not shown). Subsequent cleavage by a site 2 protease (S2P) at a site proximal to the lumenal side of
the TM produces a C-terminal fragment (CTF) and liberates Ma. As yet unidentified enzymes (marked ‘‘??’’) further cleave Ma at as yet unknown sites
to produce MaC. MaC fragments and a fragment of the PKD domain have been shown to accumulate in fibrillar stage II melanosomes [23].
doi:10.1371/journal.pgen.1002286.g001
Author Summary
Amyloid is a protein fold that is normally associated with
pathology, such as neurodegeneration in Alzheimer,
Parkinson, and Creutzfeldt–Jakob diseases. The amyloid
fold has also been exploited by nature for functional
purposes; for example, proteolytic fragments of the
pigment cell-specific integral membrane protein, PMEL,
form amyloid fibrils upon which melanin pigments
polymerize within subcellular organelles called melano-
somes. Whereas animal models that entirely lack PMEL
expression have modest pigment loss, chickens or horses
with small in-frame mutations that alter a non-amyloido-
genic region of PMEL have severe pigment loss that is
thought to be associated with pigment cell death. We
show here that these mutations alter the capacity of this
region to self-associate, likely changing the conformation
of full-length PMEL oligomers. While these changes do not
affect the intrinsic ability of PMEL to form amyloid fibrils,
they alter either the fibrils themselves or the kinetics of
fibril formation such that they form more compact
structures and inhibit melanin formation when expressed
in melanocytes in culture. Based on our results, we
speculate that minor alterations in pre-amyloid assembly
of an amyloidogenic protein influences entry into either a
benign or a pathogenic amyloid pathway.
PMEL Mutations Make Functional Amyloid Pathogenic
PLoS Genetics | www.plosgenetics.org 2 September 2011 | Volume 7 | Issue 9 | e1002286viability in vivo and in cell culture, and the dominant nature of the
mutations, we hypothesized that the TM
insWAP and TM
R625C
mutations of PMEL in the DW chicken and the Silver horse,
respectively, alter the cellular or biophysical properties of PMEL
to ultimately convert functional amyloid into a pathological form.
Here, by recapitulating these mutations in the context of human
PMEL (hPMEL), we provide evidence to support this hypothesis.
Moreover, we show that the secondary PKD
DLVVT and TM
D5
mutations in the Smoky and Dun chicken PMEL orthologues
represent null or partial null alleles that revert the pathological
effects of the TM
insWAP and TM
R625C mutations on pigmentation.
Finally, we show that changes in or near the TMD of an integral
membrane amyloidogenic protein can influence the oligomeriza-
tion of a distal lumenal fragment into functional amyloid. We
discuss these findings with regard to their potential implications for
the formation of functional vs. pathological amyloid.
Results
Mutations found in DW and HoSi PMEL alter the
oligomerization potential of the human PMEL
transmembrane domain
Human PMEL (hPMEL) forms pre-amyloid oligomers that are
stabilized by disulfide bonds [13], and a recent study found that
hPMEL formed fewer disulfide-bonded oligomers when coex-
pressed with chicken PMEL bearing the DW-associated TM
insWAP
mutation [38]. However, it is not known whether the result in that
study reflected a direct effect of the TM
insWAP mutation or an
inability of hPMEL to form the appropriate disulfide bonds with
chicken PMEL. To specifically test whether and how mutations in
or near the PMEL TMD influence PMEL oligomerization, we
introduced mutations analogous to those found in the DW chicken
(TM
insWAP) and Silver horse (TM
R625C) in the context of hPMEL
(Figure 2A). Upon expression of these mutants or wild-type full-
length hPMEL in HeLa cells, we found that the TMD mutants
were equally effective as wild-type hPMEL at forming disulfide
bonded oligomers, as detected by non-reducing SDS-PAGE and
immunoblotting (Figure S1A). These data suggest that the PMEL
mutations associated with the DW chicken and HoSi do not affect
the formation of disulfide-bonded PMEL oligomers when
presented within the context of hPMEL. The previously observed
reduction in disulfide-bonded oligomers by hPMEL upon coex-
pression of chicken DW PMEL [38] thus likely reflects the inability
of these cross-species PMEL isoforms to form oligomers, which is
supported by our inability to co-immunoprecipitate wild-type
mouse PMEL with wild-type hPMEL (data not shown).
While oligomerization of the hPMEL lumenal domain is
stabilized by disulfide bonds, it is not known whether the TMD
Figure 2. PMEL TMD mutations cause increased TMD–mediated dimerization. A. Wild-type human PMEL (hPMEL) TMD sequence (bold) and
surrounding amino acids. In the context of hPMEL, homologous mutations to those found in the DW chicken (TM
insWAP) and Silver horse (TM
R625C) are
shown in gray.B. Left, TMDsequences(bold)used tomake theToxR-TMD-MBP chimeraswith (L) or without(S)theN-terminal boundaryresiduesQE and
C-terminal boundary residues RRR. Right, MBP-deficient bacteria transformed with the indicated TMD-containing chimera were plated on medium with
maltose as the only source of carbon; shown is whether colonies grew (+) or not (-). Growth indicates proper insertion of the chimera into the bacterial
membrane.C.Representativehistogram(from atleast 3 similar experiments) ofCAT activity,representingTMD-mediateddimerizationofthechimera, as
measured spectrophotometrically and normalized to protein concentration. GA, Glycophorin A TM domain. Bars, standard deviation.
doi:10.1371/journal.pgen.1002286.g002
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lumenal domain interactions. To determine whether the hPMEL
TMD can oligomerize on its own and whether the TM
insWAP and
TM
R625C mutations influence this property, we turned to the
widely used TOXCAT assay [39]. In this assay, a chimeric protein
consisting of the transcription factor ToxR, the TMD of interest,
and maltose binding protein (MBP) is expressed in MBP-deficient
bacteria. Proper insertion of the chimeric protein into the plasma
membrane confers growth in maltose as the only carbon source,
and oligomerization mediated by the TMD activates ToxR and
stimulates ToxR-dependent transcription of the chloramphenicol
acetyl transferase (CAT) gene. Upon expression of ToxR-TMD-
MBP chimeras containing the PMEL TMD with or without the
natural border residues at either end (Figure 2B), only chimeras
lacking the C-terminal border residues, RRR (SS, LS), conferred
growth in maltose — regardless of the presence of the N-terminal
border residues, QE — despite equivalent expression of all
chimeras as determined by immunoblotting (Figure S1B). This
suggested that the C-terminal residues interfered with insertion of
the chimera into the plasma membrane with the proper
orientation. Interestingly, altering the second arginine in the C-
terminal border sequence to either Cys (R/C; as in the TM
R625C
mutant), Ser (R/S), or Lys (R/K) allowed the chimeric protein to
insert properly into the membrane, as evidenced by maltose
complementation (Figure 2B). This indicates that the TM
R625C
substitution associated with HoSi PMEL alters the properties of the
PMEL TMD.
For those chimeras that confer growth in maltose, we then
tested their ability to dimerize by measuring CAT activity using a
spectrophotometric assay (Figure 2C) [40]. As a positive control
we used a chimera containing the strongly dimerizing TMD of
Glycophorin A (GA wt), and as a negative control we used either
the vector without a TMD (no TM) or a chimera containing the
non-dimerizing Glycophorin A G83I mutant TMD (GA mut)
[39,41]. The wild-type PMEL TMD, lacking (SS) or containing
(LS) the N-terminal border residues, conferred similar CAT
activity as the negative controls. In contrast, the TM
insWAP
(InsWAP) and TM
R625C (R/C) mutations conferred substantial
CAT activity. These data indicate that whereas the wild-type
hPMEL TMD is not capable of oligomerization, both the DW-
associated TMD insertion and the HoSi-associated R/C transver-
sion facilitate TMD dimerization. Insertion of three leucines
(InsLLL) in place of the WAP insertion conferred an even slightly
higher CAT activity, suggesting that the increased dimerization
mediated by the TM
insWAP mutation is likely due to the increase in
TMD length. To test whether the R/C mutation reflected a
specific property of the cysteine (such as disulfide bond formation),
we tested whether replacement of the same arginine residue by
serine (R/S) or lysine (R/K) affected CAT activity. Interestingly,
whereas both of these mutants conferred proper insertion into the
plasma membrane as indicated by growth in maltose, the R/S
mutant, but not R/K, conferred CAT activity similar to that by
the R/C mutant. This suggests that the dimerization conferred by
the R/C mutant reflects decreased repulsion between adjacent
basic RRR (or RKR) motifs.
DW– and HoSi–associated TMD mutations do not affect
PMEL trafficking to premelanosomal compartments or
proteolytic activation
We next tested whether the altered TMD properties associated
with the TM
insWAP and TM
R625C mutations influenced PMEL
trafficking or processing. hPMEL without (wild-type) or with the
TM
insWAP or TM
R625C mutations was expressed ectopically in
non-melanocytic HeLa cells by transient transfection. As previously
shown, wild-type hPMEL expressed in these cells is enriched at
steady state within late endosomes and lysosomes [13] (Figure 3Aa–
c). Neither the TM
insWAP nor the TM
R625C mutation affected this
steady state localization, as shown by the predominant labeling for
these mutants by immunofluorescence microscopy (IFM) on the
interior of structures labeled by the late endosome/lysosome
marker, LAMP1 (Figure 3Ad–i). These data suggest that the
TMD mutations in dominant PMEL mutants do not affect hPMEL
trafficking, supporting a similar earlier conclusion for chicken DW
PMEL [38].
In order to liberate the amyloidogenic Ma fragment, PMEL
undergoes regulated proteolytic cleavage in the lumenal domain
by a proprotein convertase (PC) and an as yet unidentified site 2
protease (S2P) [17,18] (Figure 1). Ma is then further processed by
as yet unidentified proteases during fibril maturation [12,21–23].
The products of these cleavages are detected and semi-quantified
by immunoblot analysis of detergent-soluble lysates from HeLa
cells transfected with wild-type hPMEL; the characteristic Ma and
Mb fragments result from PC cleavage of full-length hPMEL [17],
the C-terminal fragment (CTF) results from S2P cleavage of Mb
[18], and the MaC fragments that are enriched in detergent-
insoluble fibrils result from further proteolysis of Ma [21]
(Figure 1). Similar levels of all fragments are present in lysates
from cells expressing TM
insWAP or TM
R625C hPMEL, with the
exception of a slight increase in the levels of the CTF relative to
Mb in cells expressing the TM
R625C mutant (Figure 3B).
Moreover, whereas wild-type and TM
insWAP hPMEL often form
two species of CTF (see doublet in Figure 3B), TM
R625C hPMEL
forms predominantly a single species. These data suggest that
TM
insWAP and TM
R625C hPMEL are effectively cleaved to
fibrillogenic fragments by the PC and by proteases within late
endosomal compartments but that S2P cleavage is favored at one
of two sites in TM
R625C hPMEL and the ensuing CTF is likely
more stable than the wild-type CTF.
To test whether processing kinetics are altered by the TMD
mutations, we analyzed PMEL maturation in transfected HeLa
cells by metabolic pulse/ chase analysis of wild-type, TM
insWAP,o r
TM
R625C hPMEL immunoprecipitated from detergent-soluble
lysates. As shown in Figure 3C, both the TM
insWAP and TM
R625C
mutant hPMEL were matured to the Golgi-processed P2 form,
cleaved to the Ma/M b forms, and disappeared from detergent-
soluble lysates with roughly wild-type kinetics (Figure 3D).
Moreover, for all hPMEL variants, Ma was secreted into the
medium with similar kinetics and efficiency, and CTF was
generated with similar kinetics (data not shown).
Altogether, these results indicate that the TMD mutations found
in the DW chicken and the Silver horse affect neither the delivery of
PMEL to late endocytic compartments nor its ability to be
processed to amyloidogenic Ma and MaC fragments.
hPMEL with TM
insWAP and TM
R625C mutations is
fibrillogenic within endosomes
PMEL fibril formation is often inferred from the detection of
detergent-insoluble MaC fragments by immunoblotting, but non-
fibrillar mutants of PMEL that form disorganized aggregates —
such as hPMEL lacking a PC cleavage site — can also generate
similar fragments [12,17]. To test whether the TM
insWAP and
TM
R625C variants are capable of supporting fibril formation,
HeLa cells transiently expressing these variants or wild-type
hPMEL were analyzed by standard electron microscopy (EM). As
shown in Figure 4, stage II-melanosome-like compartments with
fibrillar arrays were detected in cells expressing any of the hPMEL
variants, but not in cells expressing empty vector (Figure S2). As
for cells expressing wild-type hPMEL, fibrils in cells expressing
PMEL Mutations Make Functional Amyloid Pathogenic
PLoS Genetics | www.plosgenetics.org 4 September 2011 | Volume 7 | Issue 9 | e1002286PMEL Mutations Make Functional Amyloid Pathogenic
PLoS Genetics | www.plosgenetics.org 5 September 2011 | Volume 7 | Issue 9 | e1002286TM
insWAP or TM
R625C were detected within organelles that often
contained internal membrane vesicles or sheets, but not in
secretory or early endocytic compartments. Immunoelectron
microscopy (IEM) analysis using immunogold labeling of ultrathin
cryosections further showed that all of the hPMEL variants were
incorporated into the fibrils (data not shown, but see below for
incorporation of variants into melanosome fibrils in melanocytic
cells). These data indicate that the TM
insWAP and TM
R625C
mutations do not impair the intrinsic ability of hPMEL to form
fibrils within endosomal compartments.
TM
insWAP and TM
R625C mutations induce altered
morphology and melanization of hPMEL fibrils in
pigmented cells
Unlike in non-pigment cells, in which fibril maturation is
inefficient and occurs within late endosomes [13], PMEL
protofibrils in pigment cells mature efficiently into sheets [11]
that accumulate in stage II melanosomes and that then serve as
sites of melanin deposition during melanosome maturation [24].
To determine whether the TM
insWAP and TM
R625C mutations
influence fibril maturation or downstream pigmentation, we
analyzed the behavior of hPMEL with or without these mutations
expressed transiently or stably in pigment cells. In order to
distinguish the transgene from the endogenous mouse PMEL, we
expressed the hPMEL variants in ‘‘wild-type’’ mouse melanocyte
cell lines, and exploited antibodies (NKI-beteb and HMB-50) that
only detect hPMEL. By IFM, wild-type, TM
insWAP and TM
R625C
hPMEL each localized to punctate structures that partially
overlapped with late endocytic compartments marked by LAMP2
and that did not overlap with mature pigmented eumelanosomes
(Figure 5 and Figure S3). These data suggest that the wild-type,
TM
insWAP and TM
R625C hPMEL variants localize similarly in
melanocytes. Endogenous mouse PMEL does not significantly co-
localize with late endocytic markers (not shown) and thus the
partial co-localization of ectopic hPMEL with LAMP2 might
reflect less efficient delivery of this isoform to early stage
melanosomes, likely due to the low expression levels attained by
infection (see below) and the inability of hPMEL to interact with
the mouse isoform as detected by coimmunoprecipitation (data not
shown).
We next tested whether expression of the TM
insWAP and
TM
R625C hPMEL variants affect the morphology or degree of
pigmentation of individual melanosomes. In mouse melan-Ink4a
melanocyte stable transfectants that expressed very low levels of
the dominant TM
insWAP and TM
R625C hPMEL variants (,10–
20% of endogenous mouse PMEL as assessed by immunoblotting),
no changes in overall pigmentation were observed relative to cells
expressing wild type hPMEL (bright field images in Figure S3,
with melanosomes pseudocolored blue in the insets), but this is
likely due to the low expression levels (see below). Nevertheless, by
IEM of ultrathin cryosections from each of the stable cell lines,
thin and disorganized immature protofibrils (arrowheads) that
were densely immunogold labeled with anti-hPMEL antibodies
were observed within Stage I melanosomes (Figure 6a–c).
However, upon maturation of the protofibrils into elongated
fibrillar sheets, wild-type and mutant hPMEL showed strikingly
different characteristics (compare Figure 6d to 6e–f). In cells
expressing wild-type hPMEL, only very sparse immunogold
labeling was observed on the parallel sheets of organized fibrils,
and most of the organelles with thickened fibrillar sheets,
corresponding to Stage III or IV melanosomes, were densely
pigmented (Figure 6d) as has been previously reported [24]. This is
consistent with the notion that although a fraction of hPMEL is
delivered to the late endocytic pathway in mouse melanocytes,
sufficient protein is properly trafficked to melanosomes to form
fibrils. The lack of labeling on the pigmented fibrils likely reflects
epitope sequestration as pigmentation proceeds [13,14,42]. In
contrast to cells expressing wild-type hPMEL, compartments with
tightly packed fibrils that were densely immunogold labeled for
Figure 4. PMEL TMD mutants can form fibrils when overex-
pressed in non-pigmented cells. HeLa cells transiently overexpress-
ing wild-type, TM
insWAP or TM
R625C hPMEL were fixed and embedded in
epon resin for conventional electron microscopy analysis. Note that
elongated fibrils in the lumen of multivesicular endocytic compart-
ments (labeled with asterisks) are observed in cells expressing all three
variants of hPMEL. Bars, 500 nm.
doi:10.1371/journal.pgen.1002286.g004
Figure 3. TMD mutations do not affect PMEL trafficking, maturation, or processing. HeLa cells were transiently transfected with low (A
and C–D) or high (B) DNA levels of pCI plasmids encoding wild-type, TM
insWAP or TM
R625C hPMEL, and processed for analysis 48 hrs post-transfection.
A. IFM analysis. HeLa cells were fixed and co-stained with antibodies against hPMEL (red; panels a, d and g) and LAMP1 (green; panels b, e, and h).
Right panels (c, f, i) show the merged images, and insets show a 4X magnification of the boxed regions. Notice the similar pattern of labeling of wild-
type (a–c), TM
insWAP (d–f) and TM
R625C hPMEL within LAMP1-labelled late endosomes/lysosomes. Bar, 20 mm. B. Immunoblot analysis. Transfected
HeLa cells were lysed and fractionated into detergent soluble and insoluble fractions. Detergent soluble fractions (top three panels) were probed
with antibodies to either the hPMEL N-terminus to detect P1 and Ma (top), or the C-terminus to detect Mb and CTF (middle panels). Detergent
insoluble, fibril-enriched fractions were probed with HMB45 to detect the PMEL-derived MaC fragments (lower panel). Left, molecular weight
markers; right, relevant bands are indicated. C. Metabolic pulse chase/ immunoprecipitation analysis. Transfected HeLa cells were metabolically
labeled with
35S methionine/ cysteine, chased for the indicated times, and lysed in Triton X-100. PMEL was immunoprecipitated from detergent
soluble fractions using an antibody to the C-terminus. Left, molecular weight markers; right, relevant bands are indicated. D. Quantification of
abundance of relevant PMEL fragments from at least three pulse chase experiments as shown in C.; the band intensity of each fragment was
normalized to that of P1 at time zero [P1(t0)]. Bars, standard error.
doi:10.1371/journal.pgen.1002286.g003
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R625C and
especially the TM
insWAP variants (asterisks, Figure 6e–f; more
images can be found in Figure S4). The sheets seemed unusually
tightly packed with no space between the fibrils (note the spacing
between fibrils in organelles that lack labeling for the transgene,
indicated by brackets, and the loss of spacing in organelles that are
labeled for the TM
insWAP and TM
R625C transgenes). The
organelles that were immunogold labeled largely showed no overt
pigmentation, suggesting that either the fibrils were no longer
capable of binding to melanins or that they inhibited melanin
production. In some cases, particularly in cells expressing the
TM
R625C variant, labeling could be observed on the non-
pigmented periphery of melanized melanosomes (Figure S4h
and i).
To better test whether the variant hPMEL isoforms affected
overall pigmentation, we transiently expressed them in melan-
mu:MuHA, a highly pigmented mouse melanocyte cell line that is
less likely than melan-Ink4a to de-differentiate (our unpublished
observations), using recombinant retroviruses that coexpress
EGFP. The highest hPMEL expressers were enriched by cell
sorting for high EGFP expression. By immunoblotting, transgene
expression was substantially higher than in the stable transfectants
but still less than endogenous mouse PMEL expression (data not
shown). Cells were then processed for standard EM analysis.
Whereas cells expressing wild-type hPMEL were normally
pigmented as compared to cells expressing empty vector (not
shown) and harbored few stage II (unpigmented) melanosomes,
cells expressing the TM
R625C and especially the TM
insWAP variants
were hypopigmented, harbored fewer pigmented melanosomes
and were enriched in early stage melanosomes (Figure 7A–7B).
Quantification showed that cells expressing TM
insWAP hPMEL
showed an increase in non-pigmented Stage II (p=0.006) with a
concomitant loss of pigmented Stage III melanosomes (p=0.014)
as compared to wild-type hPMEL (Figure 7B, 7C); cells expressing
TM
R625C hPMEL likewise showed a decrease in Stage IV
melanosomes (p=0.027) with a concomitant increase in Stage II
(p=0.018) and Stage I melanosomes (p=0.014). Importantly,
mutant PMEL-expressing cells with the highest increase in early
stage melanosomes consistently showed the most marked decrease
in pigmented organelles, suggesting a defect in melanosome
maturation or pigment production that might be associated with
higher expression levels of mutant PMEL. Moreover, quantifica-
tion of the number of pigmented (Stage III and IV) organelles per
unit area was decreased most strikingly in cells expressing
TM
insWAP (p=0.002; Figure 7D). In cells expressing TM
R625C
there was also a tendency towards a decrease in the number of
pigmented organelles (see Figure 7A–7C), but it was not
significantly different from cells expressing wild-type PMEL
(Figure 7D), likely due to the high variability encountered in these
cells (see Figure 7B). These results suggest that even after short
Figure 5. Wild-type and TMD mutant hPMEL variants localize similarly when expressed in mouse melanocytes. Immortalized melan-
Ink4a mouse melanocytes that stably expressed wild-type (a–c), TM
insWAP (d–f)o rT M
R625C (g–i) variants of hPMEL were fixed and analyzed by IFM
relative to the lysosomal marker, LAMP2 (red), and to pigment granules visualized by bright field microscopy (BF; pseudocolored blue). Ectopic
hPMEL was detected using NKI-Beteb (green), an antibody that recognizes human PMEL, but not murine PMEL. Shown are overlaps of PMEL relative
to LAMP2 (a, d, g) or melanosomes (b, e, h) alone or together (c, f, i). Insets show a 4X magnification of the boxed areas. Note that both mutants show
a similar pattern of staining and co-localization as wild-type hPMEL. Individual labels and the original bright field images are shown in Figure S3.
doi:10.1371/journal.pgen.1002286.g005
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formed by the TM
insWAP—and to a lesser degree the TM
R625C
variant hPMEL—impair pigmentation.
Together, these results suggest that the mutations found in the
dominant DW chicken PMEL and Silver horse influence the
assembly of the fibrils into sheets, creating a tightly packed
structure that may be inaccessible to pigment and/or that inhibits
melanin biosynthesis.
The Smoky chicken mutation prevents formation of
aberrant PMEL fibrils
The Smoky chicken is a recessive revertant of the DW allele,
reflecting a second site mutation that results in deletion of four
residues from the PKD domain (PKD
DLVVT) (Figure 8A) [30]. In
homozygous form, the Smoky allele imparts modest pigment
dilution in the feathers—similar to the modest pigment dilution
observed in the silver mouse [26], the Pmel
-/- mouse [29] and the
fading vision zebrafish [28]—as compared to the dramatic loss of
pigment imparted by the dominant DW allele. To investigate how
the PKD
DLVVT mutation might reverse the DW phenotype, we
created hPMEL variants with either the PKD
DLVVT deletion alone
or together with the WAP insertion (PKD
DLVVT-TM
insWAP)a s
found in the Smoky chicken PMEL allele. The variants were
expressed in HeLa cells, and their maturation, proteolytic
processing, and trafficking were assessed by metabolic labeling/
pulse chase and immunoprecipitation analysis and by IFM. As
shown in Figure 8B, introduction of the PKD
DLVVT deletion,
either by itself or in combination with the TM
insWAP insertion,
impaired PMEL exit from the endoplasmic reticulum (ER) as
shown by a decreased maturation into the fully glycosylated, post-
Golgi P2 form. Furthermore, the PKD
DLVVT and PKD
DLVVT-
TM
insWAP hPMEL forms were not efficiently processed by
proprotein convertase cleavage into Ma and Mb fragments.
These data are reminiscent of the effects of deletion of the entire
PKD domain [16,22] and suggest that the PKD
DLVVT deletion
impairs PMEL maturation.
Although the pulse chase data suggested that the PKD
DLVVT
mutation impairs PMEL exit from the ER, a fraction of the Golgi-
modified P2 form did accumulate over time. To determine
whether this fraction of ‘‘mature’’ PKD
DLVVT PMEL is properly
trafficked to late endosomal compartments, we analyzed its
localization in HeLa cells by IFM using an antibody (HMB45)
that only recognizes Golgi-modified PMEL [12,20]. Unlike wild-
type hPMEL, this ‘‘mature’’ form of PKD
DLVVT or PKD
DLVVT-
TM
insWAP hPMEL did not localize significantly to late endosomal
compartments marked by LAMP1 (Figure 8C, central panels).
Figure 6. PMEL TMD mutants generate fibrils with aberrant morphology. Immortalized melan-Ink4a melanocytes that stably express wild-
type (a, d), TM
insWAP (b, e)o rT M
R625C (c, f) variants of hPMEL were fixed and processed for cryoimmunoelectron microscopy. Ultrathin cryosections
were immunogold labeled for hPMEL using the hPMEL-specific NKI-beteb antibody and 10 nm protein A gold. Note that dense immunolabeling is
observed on short immature fibrils (arrowheads) within stage I melanosomes from cells expressing all three hPMEL variants (upper panels, a–c), but
that mature, elongated fibrils are immunogold labeled only in compartments (asterisks) within cells expressing the TMD mutants (lower panels, d–f).
Also note the densely packed profile of the immunogold-labeled mature fibrils in cells expressing TMD mutant hPMEL as compared to the thick
pigmented fibrils that lack labeling, which are found within stage III melanosomes in cells expressing wild-type hPMEL and which show some spacing
between neighboring fibrils (bracket). Bars, 200 nm.
doi:10.1371/journal.pgen.1002286.g006
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PLoS Genetics | www.plosgenetics.org 8 September 2011 | Volume 7 | Issue 9 | e1002286Figure 7. Reduced melanosome pigmentation in melanocytes expressing PMEL TMD mutants. Immortalized melanMu:MuHA pigmented
melanocytes were transiently infected with retroviruses that encode wild-type, TM
insWAP or TM
R625C hPMEL-and co-expressed EGFP. Four days post-
infection, cells expressing high levels of hPMEL transgene were selected by flow cytometric sorting for high EGFP expression, then fixed, embedded
in epon resin, and processed for conventional thin section EM. A. Cells expressing wild-type hPMEL (left panels) show predominantly pigmented
stage III and IV (III, IV) melanosomes and few unpigmented Stage I and II melanosomes (I, II). By contrast, cells expressing either TM
insWAP (middle
panels) or TM
R625C (right panels) hPMEL variants harbor many fewer Stage IV melanosomes and many more non-pigmented, Stage I-II melanosomes.
M, mitochondria. B. The total number of melanosomes of each stage in 6–7 whole cells from each set of samples was quantified relative to the total
number of melanosomes per cell. The mean, median, maximum (max) and minimum (min) values, and 25th and 75th quartile values for distance
moved in each experimental set are shown. C. Quantification of the number of each stage melanosome divided by the number of melanosomes in
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ments labeled by internalized transferrin (Figure 8C, right panels),
much like PMEL lacking the entire PKD domain [16]. This
indicates that the PKD
DLVVT deletion impairs not only PMEL
maturation in the early biosynthetic pathway but also its selective
incorporation into ILVs for trafficking to late endosomal
compartments, thus precluding access to proprotein convertase
cleavage [16]. Consistent with the requirement for sorting to ILVs
and proprotein convertase cleavage for fibril formation, MaC
fragments are not detected in detergent-insoluble fractions of cells
expressing the PKD
DLVVT or PKD
DLVVT-TM
insWAP mutants
(Figure S5). We conclude that the PKD
DLVVT mutation reverts
the dominant phenotype of the TM
insWAP mutation by impairing
access of PMEL to fibrillogenic compartments and blocking
aberrant amyloid fibril formation.
The results described above suggest that primary PMEL
mutations that inhibit pigmentation in a dominant fashion can
be reverted by second site mutations that prevent the aberrant
PMEL variants from accumulating in fibrillogenic compartments.
The dominant but milder Dun chicken PMEL allele contains both
the orthologous TM
R625C mutation found in the HoSi allele and an
additional deletion of 5 amino acids within the TMD (TM
D5;
Figure S6A). We therefore predicted that the TM
D5 mutation, like
the Smoky-associated PKD
DLVVT mutation, would impair PMEL
accumulation within fibrillogenic endosomal compartments.
Consistent with this prediction, when expressed in HeLa cells,
introduction of the TM
D5 mutation in the context of hPMEL
decreases the expression level of all mature (post-ER) PMEL
species, including the fibrillar MaC forms (Figure S6B), even when
corrected for mRNA expression (data not shown). This likely
reflects enhanced ER-associated degradation due to poor folding
or membrane incorporation, as the material that does exit the ER
appears to be processed with normal kinetics (Figure S6C-S6D).
These data suggest that while the TM
D5 mutation does not prevent
delivery of PMEL to fibrillogenic compartments (Figure S6E), it
can impair the efficiency with which aberrant PMEL fibrils
accumulate within such compartments. Given that the primary
effect of the TM
D5 mutation is on ER exit, it is highly likely to have
similar effects in the context of the TM
R625C mutation, as in Dun
chickens, which does not affect ER exit (Figure 3).
Discussion
Unlike most commonly known forms of amyloid, which are
thought to provoke pathologic processes, PMEL is an example of a
benign and functional amyloid. Here we show how mutations in
the PMEL TMD are associated with an aberrant amyloid fibril
biogenetic pathway, altering the normally physiological amyloid to
produce a pathological form that impairs pigmentation within
melanocytes. Epidermal melanocytes from animals harboring
these mutations are depleted of melanosomes [34] and have
decreased viability in vitro and perhaps in vivo [31], suggesting that
the formation of these aberrant fibrils impairs melanosome
integrity and may be toxic to the pigment cell. Although the
TMD does not form part of the amyloid core, mutations in this
domain influence TMD oligomeric properties that reverberate
distally on the association between the amyloidogenic domains of
PMEL, as evidenced by an abnormal packing of the mutant
PMEL fibrils. We also show that secondary mutations found in
animals in which the pigment dilution associated with the primary
pathogenic TMD mutations are dampened or reverted prevent the
accumulation of these PMEL isoforms in fibrillogenic compart-
ments, thus mimicking a PMEL knockout. This finding indicates
that it is less detrimental to express no fibrils at all than to express
aberrant fibrils that inhibit pigmentation and might be toxic to the
melanocyte.
Interactions among TMDs are known to influence multisubunit
complex assembly and function in vivo [43–48]. Here, we show
that whereas the TMD of hPMEL normally does not promote
oligomerization, introduction of either the TM
insWAP or the
TM
R625C mutations found in the DW chicken or Silver horse
PMEL orthologues results in substantial oligomerization potential.
Oligomerization by the PMEL TMD was similarly enhanced by
insertion of three leucine residues in place of the DW-associated
WAP insertion, suggesting that the effect reflected increased TMD
length rather than specific amino acid side chain interactions.
Although the observed increase in dimerization by the TM
R625C
could not be directly compared to the wild-type TMD with the
extended cytosolic domain because the latter did not insert
properly into the E. coli plasma membrane, a similar degree of
oligomerization was observed upon alteration of R
625 to serine as
with the HoSi-associated cysteine, but not to lysine, all of which
supported proper membrane insertion. This suggests that
increased oligomerization mediated by the TM
R625C mutation
reflects removal of a positive charge from the TMD boundary,
decreasing the electrostatic repulsion between neighboring PMEL
molecules by the membrane proximal arginine triplet. Interest-
ingly, the TM
R625C mutation was associated with greater CTF
stability. In addition, whereas we often observed a CTF doublet
for both wild-type and TM
insWAP PMEL, reflecting the two
possible S2P sites [18], we always detected a single TM
R625C CTF
species. The altered TMD mediated oligomerization of this
mutant might thus result in either a greater accessibility of one
site over the other or aberrant partitioning of PMEL to membrane
subdomains that preferentially harbor a site-specific enzyme, akin
to what has been proposed to occur between a- and b-secretases in
the cleavage of APP to produce pathologic Ab [49].
How increased TMD-mediated dimerization might influence
PMEL folding, assembly, and fibril formation is not yet clear. A
previous study found that the DW chicken PMEL associated with
membrane microdomains to a similar degree as wild-type hPMEL
[38], suggesting that the TM
insWAP mutation does not alter
membrane partitioning. The same study suggested that matura-
tion and proteolytic processing of DW chicken PMEL was not
substantially different from that of wild-type hPMEL. Consistently,
we find that neither the TM
insWAP nor the TM
R625C mutation
affect hPMEL biosynthetic trafficking, proteolytic maturation,
delivery to ILVs within endosomes, or the initial stages of
protofibril formation. While we could not detect a previously
described effect of the TM
insWAP mutation (or of the TM
R625C
mutation) in reducing disulfide bond-mediated dimerization of the
PMEL lumenal domain [38]—which likely reflected more a lack
of heteromeric interactions between chicken and human PMEL
than an effect of the TMD mutation itself—it is highly likely that
the induced TMD interactions impact the orientation and
that field; at least 60 fields of equal size/magnification were analyzed, containing more than 400 melanosomes of different maturation stages. *, p
,0.05; **, p ,0.01 as determined by ANOVA and Student’s t-test. D. Quantification of the number of pigmented granules (Stage III-IV) per mm
2 of cell
area in cells expressing wild-type, TM
insWAP or TM
R625C hPMEL variants or cells transduced with virus that did not co-express hPMEL. Each
measurement is shown individually; median values are indicated. **, p,0.01 as determined by ANOVA and Student’s t-test.
doi:10.1371/journal.pgen.1002286.g007
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DLLVT secondary mutation found in the Smoky chicken PMEL prevents delivery of TM
insWAP mutant hPMEL to
fibrillogenic compartments. A. Sequence of PKD domain residues 245–280 in wild-type and mutant hPMEL. The PMEL gene in the Smoky chicken
harbors an in-frame deletion that eliminates four amino acids from the PKD domain, corresponding to LVVT in hPMEL (PKD
DLLVT), in addition to the
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[13,38]. Although the induced conformational changes are likely
subtle and do not impact recognition by the ER quality control
system, biosynthetic trafficking, or the ability to form fibrils, they
do appear to have downstream effects on the assembly of fibrils
into sheets and/or in the packing of the sheets. One potential
explanation for these effects is that non-amyloidogenic domains of
PMEL dimers that protrude from the fibrils and regulate the
packing of fibrils into higher order assemblies might be positioned
differently. An alternative explanation is that oligomerization via
the PMEL TMD might increase the kinetics of higher order fibril
assembly. Either effect might result in more tightly packed fibrils
within early stage melanosomes.
How might the TM
insWAP or TM
R625C PMEL variants impair
melanogenesis and melanosome integrity? If indeed increased TMD
oligomerization translates a conformational change to the lumenal
domain to alter either the mode or kinetics of fibril polymerization
into sheets, several mechanisms could be envisioned. Both altered
conformation or kinetics—either by physical blockade through
tighter packing or by overly rapid kinetics of sheet assembly—would
potentially preclude the delivery of melanogenic enzymes, such as
tyrosinase, to the lumen of the maturing melanosome [50]. This
would in turn have the effect of concentrating the formation of
oxidative melanin intermediates at the limiting membrane of the
maturing melanosome and subjecting the limiting membrane to
oxidative attack, potentially damaging the integrity of the organelle.
This would explain both the loss of melanization (this study and refs.
[31,34]), despite the presence of a potentially active tyrosinase
[34,35], and the decrease in melanosome numbers [34,35]. Release
of melanosomal contents might then impact cell viability [31].
Alternatively, it is known that melanosomes are highly enriched in
divalent cations [51–53], and PMEL has been suggested to sequester
calcium [54]; alterations to PMEL fibril packing might reduce its
ability to sequester divalent cations, with potential harmful effects on
melanosomes by further oxidative damage. Potential negative effects
on copper-dependent tyrosinase activity within melanosomes might
result from a similar loss of copper sequestration [55]. A third
possibility is that the altered conformation of the fibrils—which very
likely are a variant form of amyloid—makes them inherently toxic.
For example, Ab amyloid has been shown to insert into and disrupt
lipid bilayers [56]; a similar property of the TM
insWAP and TM
R625C
PMEL amyloid fibrils could potentially disrupt the melanosome
membrane directly, leading to a loss of melanosome integrity and
consequent loss of pigmentation. Finally, it is possible that
pigmentation and melanosome viability are disrupted by an
intermediate in fibril or sheet assembly that might persist due to a
decrease in kinetics or that might be produced only by the variants.
None of these possibilities are mutually exclusive, and it is possible
that a combination of effects inhibits pigmentation.
It has not been understood why the phenotype of the Smoky
chicken, with a PKD
DLVVT mutation in addition to the DW-
associated TM
insWAP mutation, restores substantial pigmentation
relative to the parental DW chicken [30]. We show here that the
secondary PKD
DLVVT mutation prevents the accumulation of PMEL
in fibrillogenic compartments, likely explaining the decreased
pigment dilution observed in Smokyvs.DW chickens. The PKD
DLVVT
mutation largely impairs PMEL maturation through the early
biosynthetic pathway, causing retention in the ER. Moreover, the
small fraction of PMEL that exits the ER is not selectively targeted to
multivesicular endosomes and rather accumulates in early endosomal
recycling compartments. This correlates with a lack of proprotein
convertase cleavage into Ma and Mb fragments and decreased
accumulation of PMEL fragments in detergent insoluble, fibril-
enriched fractions. The behavior of this mutant form of hPMEL is
similar to that of hPMEL in which the entire PKD domain is deleted
[16], supporting a critical role for the PKD domain in targeting
PMEL to fibrillogenic compartments and perhaps directly in
fibrillogenesis [23]. The results indicate that the Smoky allele is
functionally a PMEL null allele that counteracts the DW mutant’s
pathogenic effects on pigmentation in a recessive manner by
preventing the formation of aberrant fibrils. Thus, Smoky chickens
show a slight pigment dilution similar to that observed in PMEL
knockout mice [29] or in the hypomorphic silvermouse [26,33] rather
than a dramatic loss of eumelanin pigment as observed in the DW
chicken and Silver horse. Since melanocytes in the DW chicken show
decreased viability [31] and melanosome integrity [34], our studies
further suggest that the formation of tightly packed TM
insWAP fibrils
may be toxic to pigment cells and that it is therefore less detrimental
to the cell to have no PMEL fibrils at all.
The reversion of the dominant DW phenotype by the PKD
DLVVT
mutation in Smoky chickens suggests that a general mechanism for
averting PMEL amyloid pathology is to prevent access of the
aberrant amyloidogenic protein to compartments within which
amyloid formation occurs. The Dun chicken appears to be another
example of such a mechanism. Whereas the Dun chickenPMELallele
contains a mutation orthologous to that of the dominant TM
R625C
mutation in the toxic Silver horse PMEL, it also has a secondary
deletion of 5 amino acids in the TMD (TM
D5) [30]. Introduction of
this secondary mutation into hPMEL impairs ER exit, trafficking
through the plasma membrane (data not shown), and accumulation
of all mature PMEL species at steady state, suggesting inefficient
PMEL folding and a greater propensity for degradation. Thus, while
the mechanism is different from that of the secondary PKD
DLVVT
mutation in Smoky chickens, the overall effect of the TM
D5 mutation
in Dun chickens might be similar — a reduction of aberrant PMEL
accumulation in fibrillogenic compartments. We therefore liken this
secondary mutation to a revertant of the Silver horse phenotype. We
speculate that mutations in other toxic/ pathological forms of
amyloidogenic proteins that prevent appropriate accumulation of the
amyloidogenic species within amyloidogenic compartments will be
associated with protection from disease.
Materials and Methods
Antibodies and reagents
The mouse monoclonal antibodies used, their targets and
sources were as follows: HMB45 and NKI-Beteb to PMEL were
TM
insWAP mutation. B. Metabolic labeling/pulse chase analysis of HeLa cells transiently transfected with wild-type, PKD
DLVVT,T M
insWAP or PKD
DLVVT-
TM
insWAP variants of hPMEL. Cells were labeled, chased and Triton X-100-soluble cell lysates were immunoprecipitated with an antibody to the hPMEL
C-terminus as in Figure 3C. Note that variants bearing the PKD
DLVVT deletion, regardless of the presence of the TM
insWAP insertion, do not mature
efficiently to P2 and fail to accumulate Ma and Mb fragments. C. IFM analysis of HeLa cells transiently expressing wild-type (a–c), PKD
DLVVT (d–f)o r
PKD
DLVVT-TM
insWAP (g–i) variants of hPMEL. Cells were fixed after exposure for 30 min at 37uC to fluorophore-conjugated transferrin (Tf) to label early
sorting and recycling endosomes, then stained with an antibody that recognizes only mature PMEL (HMB45) and an anti-LAMP1 antibody. Left panels
(a, d, g) show PMEL labeling only; middle panels (b, e, h) show overlap of LAMP1 (green) and HMB45-labeled PMEL (pseudocolored red); and right
panels (c, f, i) show overlap of internalized Tf (green) and PMEL (red). Insets show a 4X magnification of the boxed areas. Note that wild-type PMEL
overlaps with LAMP1 but not internalized Tf, whereas PKD
DLLVT overlaps partially with Tf but not LAMP1.
doi:10.1371/journal.pgen.1002286.g008
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American Type Culture Collection (Manassas, VA); H4A3 to
LAMP1 was from Developmental Studies Hybridoma Bank
(University of Iowa, Iowa City, IA). The rabbit polyclonal
antibodies used, their targets and sources were aPep13h to the
C-terminal peptide of hPMEL [13], aPmel-N to the N-terminal
peptide of hPMEL [17], a-LAMP1 from Affinity BioReagents
(Golden, CO), and a-MBP from New England Biolabs (Beverly,
MA). Rat a-LAMP2 was from Developmental Studies Hybridoma
Bank. Unless otherwise specified, chemicals were obtained from
Sigma-Aldrich (St. Lois, MO). Tissue culture reagents were from
Invitrogen (Carlsbad, CA). FuGENE-6 and hygromycin were from
Roche Diagnostics (Indianapolis, IN).
DNA constructs and cloning
Wild-type hPMEL (long form) in pCI has been described [13]
and was used as a template for site directed mutagenesis via PCR
to generate the TM
insWAP,T M
R625C, PKD
DLVVT, PKD
DLVVT-
TM
insWAP,T M
D5 mutations; the primers used are indicated in
Table S1. Wild-type and mutant hPMEL XhoI-NotI inserts from
pCI were subcloned into pBMN-IRES-Hygro (a gift from R.
Scheller, Genentech, San Francisco, CA) or pBMN-IRES-EGFP
retroviral vectors for stable or transient infection, respectively. For
the TOXCAT assays, the pccKan expression vector was used.
The pccGpA WT and pccGpA G83I mutant derivatives of
pccKan, encoding wild-type or mutant glycophorin A, as well as
the MBP deficient Escherichia coli (malE
-) have been described [39].
PMEL wild-type or mutant TMDs were PCR-amplified from their
pCI templates and cloned into the NheI-BamHI sites of pccKan.
All plasmid inserts were verified by DNA sequencing.
Maltose complementation and TOXCAT
malE
- bacteria were transformed with pccKan or its derivatives
encoding the ToxR-TMD-MBP chimeras. Ampicillin resistant
colonies were selected, grown to mid-log phase in Luria Broth,
streaked over amp-M9 agar plates with either glucose (positive
control) or maltose as the only source of carbon [39], and
incubated for 2–4 days at 37uC. CAT activity of clones that grew
in maltose was measured using a spectrophotometric assay [40].
Briefly, the pellet from 1 ml of OD600=0.75 culture was
resuspended in 300 ml of sonication buffer (25 mM Tris pH 7.8
2 mM EDTA), sonicated, and centrifuged 30 min at 4uC, 13000 x
g to obtain cell free extracts. 10 ml of lysate was combined with
230 ml of CAT reaction buffer (100 mM Tris pH 7.8, 0.4 mg/ml
DTNB, 0.1 M AcetylCoA) and the A
412 nm was recorded every
minute for 5 min to obtain the background. Then, 10 mlo f
2.5 mM chloramphenicol was added to initiate the CAT reaction
and the A
412 nm was recorded every minute for 30 min to
determine the CAT activity according to the method by Shaw
[40]. The change in A
412 nm was linear throughout the
experiment.
Cell culture and transgene expression
HeLa cells were grown as described previously [13] and
transiently transfected with 0.1 mg DNA/ 3-cm dish for low or
7.5 mg DNA/ 10-cm dish for high transgene expression using
FuGENE-6 according to the manufacturer’s instructions. HeLa
cells were analyzed either 48 hrs (immunofluorescence microsco-
py, metabolic labeling/pulse chase and immunoblotting) or 72–
96 hrs (electron microscopy) post-transfection. The immortalized
mouse melanocyte cell lines melan-Ink4a [57] and melan-
mu:MuHA rescued cells (MuHA; [58]) were grown as described
previously [57] and stably or transiently infected with the retroviral
vectors described above. Stable melan-Ink4a transductants were
selected with 200–400 mg hygromycin B and processed for
immunofluorescence (IFM) or immunoelectron microscopy (IEM).
Transiently infected MuHA cells were sorted (University of
Pennsylvania Cell Sorting Core Facility, Philadelphia, PA) for high
EGFP expression 96 hrs post-infection and processed for conven-
tional electron microscopy (EM).
Immunofluorescence microscopy
Cells were fixed with 2% formaldehyde, incubated with primary
and fluorochrome-conjugated secondary antibodies as described
previously [13] and analyzed on a DM IRBE microscope (Leica
Microsystems, Wetzlar, Germany). Digital images were captured
with an Orca camera (Hamamatsu, Bridgewater, NJ) and
deconvolved and manipulated with OpenLab software (Improvi-
sion, Lexington, MA). Insets were magnified using Adobe
Photoshop (Adobe Systems, Mountain View, CA). For recycling
endosome labeling by continuous transferrin (Tf) uptake, HeLa
cells were starved in serum-free media containing 0.5% BSA
15 mM HEPES for 30 min at 37uC, incubated with 7.5 mg/ml
Alexafluor488-conjugated human Tf (Molecular Probes, Eugene,
OR) diluted in starvation media for an additional 30 min at 37uC,
fixed, and processed for IFM as indicated above.
Electron microscopy
For conventional electron microscopy, cells were fixed in 2%
glutaraldehyde 4% paraformaldehyde, dehydrated and embedded
in epon resin. Ultrathin sections were contrasted with 2% uranyl
acetate and analyzed by transmission electron microscopy. For
immunoelectron microscopy (IEM), cells were fixed with 2%
paraformaldehyde 0.5% glutaraldehyde and ultrathin frozen
sections were single- or double-immunogold labeled as described
previously [14,59] using Protein A gold conjugates. For quantifi-
cation of numbers of Stage I-IV melanosomes, at least 50 random
fields of each cell type (.400 compartments) were analyzed.
Immunoblotting, metabolic labeling/pulse chase, and
immunoprecipitation analyses
For immunoblotting, cells were harvested with 5 mM EDTA in
PBS, washed with 30 mM NEM in PBS, and frozen. Thawed cells
were lysed with TX-100 lysis buffer as described previously [60] in
the presence of protease inhibitors and NEM and fractionated into
detergent soluble and insoluble fractions by centrifugation. For
metabolic labeling, cells were harvested with trypsin-EDTA,
starved for 30 min in methionine/cysteine free media, labeled
with
35S methionine-cysteine for 30 min and chased for the
indicated periods of time. Cells were then lysed as indicated above
and detergent soluble fractions were immunoprecipitated with
antibodies directed to the C-terminus of hPMEL, followed by
SDS-PAGE fractionation and analysis with a STORM Phosphor-
Imager and ImageQuant software (GE Healthcare, Buckingham-
shire, United Kingdom).
Supporting Information
Figure S1 TMD mutations do not influence hPMEL covalent
oligomerization and expression of TMD mutant chimeras in E.
coli. A. HeLa cells transiently transfected with wild-type (wt),
TM
insWAP or TM
R625C variants of hPMEL were lysed, and Triton
X-100 soluble fractions were fractionated by SDS-PAGE in the
absence (-2ME) or presence (+2ME) of 2-mercaptoethanol.
Immunoblots were probed with an antibody to the N-terminus
of hPMEL. Note that the three variants migrate identically under
both non-reducing and reducing conditions, indicating that each
variant is capable of generating appropriate interchain disulfide
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either untransformed (untrfm.) or transformed to express the
indicated ToxR- PMEL-TM-MBP chimeric proteins were frac-
tionated by SDS-PAGE and probed withanti-MBP antibody(IB: a-
MBP). Note that all fusion proteins were expressed at similar levels.
(TIF)
Figure S2 Absence of fibrillar compartments in HeLa cells that
do not express PMEL variants. HeLa cells transiently transfected
with empty pCI vector were fixed and embedded in epon resin for
conventional electron microscopy analysis, as in Figure 4. Note the
absence of fibrillar structures that are observed in cells expressing
either wild-type or TMD variant forms of hPMEL (Figure 4) and
the presence of numerous multivesicular/ multilaminar, electron
dense lysosomes (L). M, mitochondria. Bar, 500 nm.
(TIF)
Figure S3 Localization of wild-type, TM
insWAP and TM
R625C
hPMEL variants relative to lysosomes and pigment granules in
melanocytes. Shown are individual panels of the overlays shown in
Figure 5 for immortalized melan-Ink4a cells stably expressing
wild-type (WT; top panels), TM
insWAP (middle panels) or TM
R625C
(bottom panels) variants of hPMEL. See legend to Figure 5 for
details. Left, labeling for hPMEL variants only (green). Middle,
labeling for LAMP2 only (red). Right, bright field images of
pigment granules only. Insets, 4X magnifications of boxed regions,
showing overlap of hPMEL variant (green) with LAMP1 (red; left
panels), pigment granules (pseudocolored blue; middle panels), or
with both (right panels). Bar, 10 mm.
(TIF)
Figure S4 PMEL TMD mutants form aberrantly packed fibrils
within pigmented cells. Immortalized melan-Ink4a melanocytes
that stably express wild-type (a–c), TM
insWAP (d–f )o rT M
R625C (g–i)
variants of hPMEL were fixed and processed for cryoimmunoelec-
tron microscopy. Ultrathin cryosections were immunogold labeled
for hPMEL using the hPMEL-specific NKI-beteb antibody and 10
nm protein A gold; shown are additional images to complement
those in Figure 6. Note the presence of aberrantly packed,
unpigmented compartments (asterisks) that are densely labeled with
antibodiesagainst hPMEL only incellsexpressing theTMDmutant
isoforms. Melanosomes of stage I, II, III and IV are indicated. Scale
bar, 0.2 mm except in panel a, in which it represents 0.5 mm.
(TIF)
Figure S5 PKD
DLVVT deletion found in Smoky chickens elimi-
nates the formation of detergent-insoluble MaC fragments by
hPMEL. HeLa cells transiently transfected with wild-type (wt),
TM
insWAP, PKD
DLVVT, PKD
DLVVT –TM
insWAP,o rT M
R625C
variants of hPMEL were lysed and fractionated into detergent
soluble (S) and insoluble (I) fractions. Identical cell equivalents of
each fraction were separated by SDS-PAGE and analyzed by
immunoblotting with HMB45 anti-PMEL antibody. Left, molec-
ular weight markers; right, full-length Ma and fibril-associated
MaC fragments are indicated. Note the absence of HMB45-
reactive bands in cells expressing the PKD
DLVVT and PKD
DLVVT –
TM
insWAP variants.
(TIF)
Figure S6 The TM
D5 mutation found in Dun chickens impairs
hPMEL maturation. A. Sequence of TMD residues 596-627 in
wild-type and TM
D5 variant hPMEL. The PMEL gene in the Dun
chicken harbors an in-frame deletion that eliminates five amino
acids from the middle of the TMD, in addition to the TM
R625C
mutationthat isalsofoundintheSilverhorsePMEL.B.Immunoblot
analysis. Transfected HeLa cells expressing wild-type (wt) or TM
D5
hPMEL variants were lysed and fractionated into detergent soluble
and insoluble fractions. Detergent soluble fractions (top three
panels) were probed with antibodies to either the hPMEL N-
terminus to detect P1 and Ma (top), or the C-terminus to detect Mb
and CTF (middle panels). Detergent insoluble, fibril-enriched
fractions were probed with HMB45 to detect the PMEL-derived
MaC fragments (lower panel). Left, molecular weight markers;
right, relevant bands are indicated. C. Metabolic labeling/pulse
chase analysis of HeLa cells transiently transfected with wild-type or
TM
D5 variant hPMEL. Cells were labeled, chased and Triton X-
100-soluble cell lysates were immunoprecipitated with antibody to
the hPMEL C-terminus as in Figure 3C. D. Quantification of
abundance of relevant PMEL fragments from the pulse/ chase
experiment shown in C.; the band intensity of each fragment was
normalized to that of P1 at time zero [P1(t0)]. Note the reduced
fraction of all TM
D5 post-ER bands. E. IFM analysis of HeLa cells
transiently expressing TM
D5 variant hPMEL. Cells were labeled
with NKI-beteb monoclonal antibody to PMEL (left, red) and with
anti-LAMP1 antibody (overlay shown on the right). Insets show a
4X magnification of the boxed region. Note the presence of TM
D5
variant hPMEL within structures circled by LAMP1, as observed
for wild-type hPMEL (see Figure 3A).
(TIF)
Table S1 Primers used to make full-length hPMEL mutants.
(DOC)
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